Clinical Values of Automated Electronic Alert for Acute Kidney Injury

Acute Kidney Injury Clinical Trial

Official title:

Clinical Values of Automated Electronic Alert for Acute Kidney injury-a Prospective ,Randomly Controlled Cohort Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02793167
• Other study ID #: GGH2016-1
• Status: Completed
• Phase: N/A
• Start date: March 2016
• Est. completion date: June 2022

Study information

• Verified date: February 2023
• Source: Guangdong Provincial People's Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Acute kidney injury (AKI) is common, serious and expensive.It is associated with significant mortality, morbidity and increased length of hospital stay.To improve clinical outcomes of AKI by early detection and timely referral to the renal,the investigators developed an electronic alert system which identifies all cases of AKI occurring in patients over 18 years.The system was also designed to collect data on AKI incidence one of the biggest tertiary hospital in China.

Description:

A prospective, randomly controlled cohort study will be conducted agmong the patients with AKI who are detected by the use of AKI sniffer. The investigators chose to assess all inpatient serum creatinine results using a combination of "KDIGO" criteria.

The investigators randomly divided the patients into two groups:

1. Usual care : patients will receive standard clinical care by the primary physicians

2. AKI alert : an AKI alert will be sent to the the doctor in charge. Our team of kidney experts would give a suggestion if the the doctor in charge issue consultation applications.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2000
• Est. completion date: June 2022
• Est. primary completion date: December 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• adult patients with an Alert for AKI(based on KDIGO guidelines)

Exclusion Criteria:

• patients already on dialysis for AKI at the time of alert

• patients with End stage renal disease

• patients <18 years of age

• patients dissenting from participation according to the Ethics application

Related Conditions & MeSH terms

• Acute Kidney Injury
• Wounds and Injuries

Intervention

Device:
• AKI alert

Locations

Country	Name	City	State
China	Nephrology Dept,Guangdong General Hospital	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
XinLing Liang

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse events during hospitalization	cardiac shock/ need for intensive care/ cardiopulmonary resuscitation/ cardiac death/ death	from start of AKI to discharge,up to 4 weeks
Primary	Incidence of cardiovascular disease and its occurrence time followed up for 1 years	heart failure/ acute coronary syndrome/ readmission/cardiac readmission/ cardiovascular intervention or surgery	One year after discharge
Primary	The AKI outcome and its occurrence time followed up for 1 years	AKI recovery/stop renal replacement therapy	One year after discharge
Primary	AKI recovery/stop renal replacement therapy	Glomerular filtration rate decreased/ new occurrence proteinuria/ original proteinuria aggravation	from start of AKI to discharge,up to 4 weeks
Secondary	Proportion of nephrology referral		from start of AKI to discharge,up to 4 weeks
Secondary	Diagnostic rate of AKI at discharge		from start of AKI to discharge,up to 4 weeks
Secondary	Follow-up rate after discharge		One year after discharge